Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ORIC Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ORIC
Nasdaq
2834
www.oricpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Feb 7th, 2025 9:30 pm
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- Jan 27th, 2025 9:15 pm
Oric Pharmaceuticals announces clinical supply agreement with Janssen
- Jan 14th, 2025 1:35 pm
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
- Jan 13th, 2025 1:05 pm
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
- Jan 13th, 2025 1:00 pm
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2025 9:15 pm
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
- Nov 12th, 2024 9:05 pm
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Oct 23rd, 2024 11:00 am
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
- Oct 15th, 2024 12:17 pm
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Oct 9th, 2024 8:15 pm
ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock
- Sep 14th, 2024 9:35 pm
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
- Aug 12th, 2024 8:05 pm
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
- Aug 5th, 2024 8:15 pm
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
- Jul 17th, 2024 3:20 pm
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
- Jul 16th, 2024 8:59 pm
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
- Jul 9th, 2024 11:30 am
Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?
- Jul 8th, 2024 10:00 pm
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
- May 8th, 2024 11:29 am
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- May 6th, 2024 8:05 pm
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- Apr 15th, 2024 8:15 pm
Scroll